ID

36602

Descrizione

Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025); ODM derived from: https://clinicaltrials.gov/show/NCT02007070

collegamento

https://clinicaltrials.gov/show/NCT02007070

Keywords

versioni (1)
  1. 26/05/19 26/05/19 -
Titolare del copyright

See clinicaltrials.gov

Caricato su

26 maggio 2019

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Non-small Cell Lung Cancer NCT02007070

Inglese

Eligibility Non-small Cell Lung Cancer NCT02007070

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
histologically or cytologically confirmed diagnosis of non-small cell lung cancer (nsclc) that is pd-l1 positive per central laboratory review
Descrizione

Non-Small Cell Lung Carcinoma PD-L1 Positive

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0007131
UMLS CUI [1,2]
C4284303
at least one measurable lesion.
Descrizione

Measurable lesion Quantity

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1513041
UMLS CUI [1,2]
C1265611
radiographic progression of nsclc after treatment with a platinum-containing doublet for stage iiib/iv or recurrent disease
Descrizione

Non-Small Cell Lung Carcinoma Progression Radiography | Therapy Double Platinum-Based | Disease TNM clinical staging | Recurrent disease

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0007131
UMLS CUI [1,2]
C0242656
UMLS CUI [1,3]
C0034571
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C0205173
UMLS CUI [2,3]
C1514162
UMLS CUI [3,1]
C0012634
UMLS CUI [3,2]
C3258246
UMLS CUI [4]
C0277556
eastern cooperative oncology group (ecog) performance scale 0 or 1
Descrizione

ECOG performance status

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1520224
adequate organ function
Descrizione

Organ function

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0678852
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
systemic cytotoxic chemotherapy, biological therapy, or major surgery within 3 weeks of the first dose of trial treatment
Descrizione

Cytotoxic Chemotherapy Systemic | Biological treatment | Major surgery

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0677881
UMLS CUI [1,2]
C0205373
UMLS CUI [2]
C1531518
UMLS CUI [3]
C0679637
systemic steroid therapy within 3 days prior to the first dose of trial treatment or any other form of immunosuppressive medication
Descrizione

Steroid therapy Systemic | Immunosuppressive Agents

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0149783
UMLS CUI [1,2]
C0205373
UMLS CUI [2]
C0021081
expected to require any other form of systemic or localized antineoplastic therapy while on trial
Descrizione

Cancer treatment Systemic Required | Cancer treatment Localized Required

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0920425
UMLS CUI [1,2]
C0205373
UMLS CUI [1,3]
C1514873
UMLS CUI [2,1]
C0920425
UMLS CUI [2,2]
C0392752
UMLS CUI [2,3]
C1514873
history of prior malignancy, with the exception of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, or in situ cancer
Descrizione

Malignant Neoplasms | Exception Basal cell carcinoma | Exception Superficial carcinoma of urinary bladder | Exception Squamous cell carcinoma of skin | Exception Carcinoma in Situ

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0006826
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0007117
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C1336527
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0553723
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C0007099
active central nervous system (cns) metastases and/or carcinomatous meningitis
Descrizione

CNS metastases | Meningeal Carcinomatosis

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0686377
UMLS CUI [2]
C0220654
active autoimmune disease or documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents
Descrizione

Autoimmune Disease Requirement Systemic steroids | Autoimmune Disease Requirement Immunosuppressive Agents

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0004364
UMLS CUI [1,2]
C1514873
UMLS CUI [1,3]
C2825233
UMLS CUI [2,1]
C0004364
UMLS CUI [2,2]
C1514873
UMLS CUI [2,3]
C0021081
prior therapy with an anti-pd-1, anti-pd-l1, anti-pd-l2, anti-cd137, or anti-cytotoxic t-lymphocyte-associated antigen-4 (ctla-4) antibody
Descrizione

Prior Therapy | Anti-PD1 Monoclonal Antibody | Anti-PD-L1 Monoclonal Antibody | PD-L2 Monoclonal Antibody | CD137 Monoclonal Antibody | Anti-CTLA-4 Monoclonal Antibody

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1514463
UMLS CUI [2]
C4289970
UMLS CUI [3]
C4289971
UMLS CUI [4,1]
C1705357
UMLS CUI [4,2]
C0003250
UMLS CUI [5,1]
C0214721
UMLS CUI [5,2]
C0003250
UMLS CUI [6]
C4289973
concurrent or past history of interstitial lung disease
Descrizione

Lung Disease, Interstitial

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0206062
pregnant or breast-feeding, or expecting to conceive or father children within the projected duration of the study, starting with screening visit through 120 days after the last dose of pembrolizumab
Descrizione

Pregnancy | Breast Feeding | Pregnancy Expected | Reproduction Expected

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3,1]
C0032961
UMLS CUI [3,2]
C1517001
UMLS CUI [4,1]
C0035150
UMLS CUI [4,2]
C1517001
Ritorna all'inizio della pagina

Similar models

Eligibility Non-small Cell Lung Cancer NCT02007070

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Non-Small Cell Lung Carcinoma PD-L1 Positive
Item
histologically or cytologically confirmed diagnosis of non-small cell lung cancer (nsclc) that is pd-l1 positive per central laboratory review
boolean
C0007131 (UMLS CUI [1,1])
C4284303 (UMLS CUI [1,2])
Measurable lesion Quantity
Item
at least one measurable lesion.
boolean
C1513041 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
Non-Small Cell Lung Carcinoma Progression Radiography | Therapy Double Platinum-Based | Disease TNM clinical staging | Recurrent disease
Item
radiographic progression of nsclc after treatment with a platinum-containing doublet for stage iiib/iv or recurrent disease
boolean
C0007131 (UMLS CUI [1,1])
C0242656 (UMLS CUI [1,2])
C0034571 (UMLS CUI [1,3])
C0087111 (UMLS CUI [2,1])
C0205173 (UMLS CUI [2,2])
C1514162 (UMLS CUI [2,3])
C0012634 (UMLS CUI [3,1])
C3258246 (UMLS CUI [3,2])
C0277556 (UMLS CUI [4])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance scale 0 or 1
boolean
C1520224 (UMLS CUI [1])
Organ function
Item
adequate organ function
boolean
C0678852 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Cytotoxic Chemotherapy Systemic | Biological treatment | Major surgery
Item
systemic cytotoxic chemotherapy, biological therapy, or major surgery within 3 weeks of the first dose of trial treatment
boolean
C0677881 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C1531518 (UMLS CUI [2])
C0679637 (UMLS CUI [3])
Steroid therapy Systemic | Immunosuppressive Agents
Item
systemic steroid therapy within 3 days prior to the first dose of trial treatment or any other form of immunosuppressive medication
boolean
C0149783 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C0021081 (UMLS CUI [2])
Cancer treatment Systemic Required | Cancer treatment Localized Required
Item
expected to require any other form of systemic or localized antineoplastic therapy while on trial
boolean
C0920425 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C1514873 (UMLS CUI [1,3])
C0920425 (UMLS CUI [2,1])
C0392752 (UMLS CUI [2,2])
C1514873 (UMLS CUI [2,3])
Malignant Neoplasms | Exception Basal cell carcinoma | Exception Superficial carcinoma of urinary bladder | Exception Squamous cell carcinoma of skin | Exception Carcinoma in Situ
Item
history of prior malignancy, with the exception of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, or in situ cancer
boolean
C0006826 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C1336527 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0553723 (UMLS CUI [4,2])
C1705847 (UMLS CUI [5,1])
C0007099 (UMLS CUI [5,2])
CNS metastases | Meningeal Carcinomatosis
Item
active central nervous system (cns) metastases and/or carcinomatous meningitis
boolean
C0686377 (UMLS CUI [1])
C0220654 (UMLS CUI [2])
Autoimmune Disease Requirement Systemic steroids | Autoimmune Disease Requirement Immunosuppressive Agents
Item
active autoimmune disease or documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents
boolean
C0004364 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
C2825233 (UMLS CUI [1,3])
C0004364 (UMLS CUI [2,1])
C1514873 (UMLS CUI [2,2])
C0021081 (UMLS CUI [2,3])
Prior Therapy | Anti-PD1 Monoclonal Antibody | Anti-PD-L1 Monoclonal Antibody | PD-L2 Monoclonal Antibody | CD137 Monoclonal Antibody | Anti-CTLA-4 Monoclonal Antibody
Item
prior therapy with an anti-pd-1, anti-pd-l1, anti-pd-l2, anti-cd137, or anti-cytotoxic t-lymphocyte-associated antigen-4 (ctla-4) antibody
boolean
C1514463 (UMLS CUI [1])
C4289970 (UMLS CUI [2])
C4289971 (UMLS CUI [3])
C1705357 (UMLS CUI [4,1])
C0003250 (UMLS CUI [4,2])
C0214721 (UMLS CUI [5,1])
C0003250 (UMLS CUI [5,2])
C4289973 (UMLS CUI [6])
Lung Disease, Interstitial
Item
concurrent or past history of interstitial lung disease
boolean
C0206062 (UMLS CUI [1])
Pregnancy | Breast Feeding | Pregnancy Expected | Reproduction Expected
Item
pregnant or breast-feeding, or expecting to conceive or father children within the projected duration of the study, starting with screening visit through 120 days after the last dose of pembrolizumab
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0032961 (UMLS CUI [3,1])
C1517001 (UMLS CUI [3,2])
C0035150 (UMLS CUI [4,1])
C1517001 (UMLS CUI [4,2])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial